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The US National Health and Social Life Survey 
(NHSLS) estimates that approximately 31% of men 
suffer from a sexual dysfunction in their lifetime.[1] The 
aim of this review is to provide family practitioners 
with an approach to managing the common types of 
male sexual dysfunction.
Method 
This review reflects the consensus and guidelines of the International 
Society of Sexual Medicine (ISSM), the recommendations of the 
International Consultation of Sexual Medicine-5 (ICSM-5), the 
Journal of Sexual Medicine and the guidelines of the European 
Association of Urology (EAU), the American Urological Association 
(AUA), the International Society for the Study of the Aging Male 
(ISSAM) and the Endocrinology Society. Our guidelines and 
recommendations aim to be evidence based and patient centred.
Erectile dysfunction 
Erectile dysfunction (ED) and premature ejaculation are the two 
most common complaints of male patients presenting with sexual 
dysfunction.[2] ED is defined as a man’s consistent or recurrent 
inability to attain and/or maintain penile erection sufficient for 
satisfactory sexual activity.[3] Symptoms include a marked difficulty 
in obtaining an erection during sexual activity and/or maintaining 
an erection until the completion of sexual activity, and a marked 
decrease in erectile rigidity.
Epidemiology
Globally, studies show a high prevalence[4-7] and incidence of 
ED,[4,8,9] correlating with general dissatisfaction, age and other 
sexual dysfunctions.[5,7] In South Africa, an exploratory study at a 
primary healthcare clinic in KwaZulu-Natal demonstrated an overall 
prevalence of 64.9% (N=521) in a sample of men aged ≥18 years.[10] ED 
increased with age, and showed a strong correlation with economic 
status and comorbid conditions.
Clinical evaluation
Up to 50% of men with ED also experience premature ejaculation 
(PE).[11] Detailed history-taking that is sensitive to the patient’s 
personal, cultural and ethnic background, and having the partner 
attend and engage in the clinical interview, assist in clarifying 
symptoms and refining the diagnosis. 
Assessment tools
The International Index of Erectile Function-15 (IIEF-15) provides 
a domain score (IIEF-EF) for erectile function that has proven to 
be a reliable pretreatment screening tool and post-treatment response 
tool.[12] A recent study indicated that patients complaining of severe ED 
probably have other comorbid conditions.[13] A more comprehensive 
medical assessment is recommended in these instances, regardless of 
the patient’s age.
Physical examination
The physical examination (i) assists in corroborating aspects of the 
medical history; (ii) reveals unsuspected physical findings; (iii) assists 
in identifying specific aetiologies or comorbidities; and (iv) creates an 
opportunity to inform the patient about aspects of his sexual anatomy 
or physiology while providing reassurance about body appearance 
and function.[14] However, the physical examination can be a source 
of shame, embarrassment, or discomfort for many and every effort 
should be made to ensure the patient’s privacy, confidentiality and 
personal comfort.
Treatment
The primary goal is to enable the individual or couple to enjoy a 
satisfactory sexual experience. This involves (i) identifying and 
treating any curable causes of ED; (ii) initiating lifestyle change 
and risk factor modification; and (iii) providing education and 
counselling to patients and their partners.[15] Medical treatments 
for ED include oral agents, local therapies and vacuum constriction 
devices. All patients with ED should be evaluated for testosterone 
levels before treatment begins.
Oral agents
Drugs that inhibit phosphodiesterase type 5 (PDE5) increase arterial 
blood flow, which leads to smooth muscle relaxation, vasodilation, 
and penile erection. Three potent selective PDE5 inhibitors have 
been approved and are available in South Africa – sildenafil (Viagra), 
tadalafil (Cialis), and vardenafil (Levitra). These medications are 
efficacious and safe, both in non-selected populations of men with 
ED and in specific subgroups.[16-18] PDE5 inhibitors do not initiate 
erections, but require sexual stimulation to facilitate an erection. 
It is currently recommended that patients should receive 8 doses 
of a PDE5 inhibitor on demand, with sexual stimulation, before 
classifying the patient as a non-responder.[16-18] Daily dosing with 
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tadalafil 5 mg has been approved for use 
in patients with ED, and recently in those 
with ED and lower urinary tract symptoms, 
by the European Medicines Agency and the 
US Food and Drug Administration. PDE5 
inhibitors are contraindicated in men using 
nitrates.[16-18] 
Local therapies
Both intracavernosal injections and intra-
urethral alprostadil are effective and well 
tolerated and used as second-line therapies.[19] 
Intracavernosal injections should not be used 
in men with conditions such as sickle cell 
disease, multiple myeloma and leukaemia, 
which predispose them to priapism.
Vacuum constriction devices are considered 
as first-line therapy by the British Society 
for Sexual Medicine. However, side-effects 
include painful ejaculation, inability 
to ejaculate, petechiae, bruising and 
numbness.[19] Penile prostheses can be fitted 
in patients in whom medical therapy has 
failed or is contraindicated, or in whom 
other therapies have failed to satisfy the 
highly motivated patient. 
Psychotherapy 
Psychotherapy focuses on (i) reducing 
or eliminating performance anxiety; (ii) 
understanding the context in which men 
or a couple make love; (iii) implementing 
psychoeducation; and (iv) modifying 
sexual scripts, and identifying and reducing 
resistance to premature discontinuation 
of pharmacotherapy.[14] While a variety of 
psychological interventions are available, 
efficacy and effectiveness studies are 
lacking.
Erectile dysfunction and 
coronary artery disease 
ED and coronary artery disease share the 
same risk factors.[20] While sexual activity 
for couples in a stable relationship does 
not increase cardiac events and sex is not 
an undue stress to the heart, men with ED 
should have their coronary artery disease 
risks assessed and treated. Sexual activity 
safety can be assessed using non-invasive 
stress testing, while exercise stress testing 
and computed coronary angiography can 
be used to detect occult coronary artery 
disease. The association between depression, 
ischaemic heart disease, and cardiovascular 
mortality has been well documented.[21] 
Depression is also associated with sexual 
dysfunction and most frequently with ED. 
Therefore, irrespective of whether ED is a 
symptom or a cause of depression, a cardiac 
patient who is depressed is more likely to 
have ED (Fig. 1).
Premature ejaculation 
The prevalence of PE is estimated at 
24.9%.[22] Lifelong PE is defined as 
ejaculation that  ‘always or nearly always 
occurs prior to or within about one minute 
of vaginal penetration’, and/or ‘the inability 
to delay ejaculation on all or nearly all 
vaginal penetrations’, coupled with ‘negative 
personal consequences such as distress, 
bother, frustration and/or the avoidance of 
sexual intimacy’.[23] PE may be the result of 
urological dysfunction, thyroid dysfunction 
or psychological and/or relationship 
problems. While most men with lifelong 
PE do not suffer from concomitant ED, 
PE coexists in about one-third of patients 
complaining of ED.[24] All patients with PE 
must be carefully screened for ED. In some 
instances, PE and ED reduce a man’s level 
of excitation (which can lead to ED), or a 
man trying to achieve an erection attempts 
to do so by increasing his excitation and 
arousal (which can lead to PE). PE may 
also occur when a man has an unstable 
erection because of a fluctuation in penile 
blood flow. In this case, the man may reach 
ejaculation quickly to compensate for the 
weak erection.
Clinical evaluation
Family practitioners should elicit details from 
the patient about the ejaculatory response, 
including his subjective assessment of his 
intravaginal ejaculatory latency time and 
sense of ejaculatory control.[14] Furthermore, 
clinicians should enquire about the patient’s 
level of sexual dissatisfaction, distress, 
and frequency of sexual activity. Included 
in this evaluation should be the partner’s 
assessment of the patient’s complaint and 
whether the partner suffers from sexual 
dysfunction. It is important to note that 
ejaculation is not equal to orgasm.
Treatment
All symptomatic therapies for PE aim 
to reduce excitation. Therefore, these 
treatments must be prescribed to patients 
who are able to obtain and maintain an 
erection until their (premature) ejaculation. 
Oral agents
The efficacy and safety of off-label daily dosing 
with selective serotonin re-uptake inhibitors 
(SSRIs) (paroxetine, sertraline, citalopram 
and fluoxetine),[25] the serotonergic tricyclic 
clomipramine, and off-label on-demand 
dosing with clomipramine for the treatment 
of PE are well established. [26] A meta-analysis 
of published data suggests that paroxetine 
exerts the strongest ejaculation delay.[27] 
Recently, dapoxetine (a short-acting SSRI) 
has been officially approved in Europe 
and some other countries for on-demand 
treatment of PE.[28] The efficacy and safety 
of off-label on-demand topical anaesthetic 
agents have also been demonstrated.[29] 
However, there is currently no evidence 
to suggest that selective dorsal nerve 
neurotomy or hyaluronic acid gel glans penis 
augmentations are effective treatments for 
PE.[14] Surgery, which may be associated 
with permanent loss of sexual function, is 
contraindicated.
Psychotherapy
Besides teaching self-control techniques to 
delay ejaculation, psychosexual therapies 
attempt to help the patient to recover his 
self-confidence and confidence in his 
sexual performance, reduce performance 
anxiety, solve rational problems, increase 
communication between partners, and 
resolve interpersonal issues that precipitate 
and maintain the dysfunction.[14] However, 
efficacy and effectiveness studies are lacking. 
Orgasmic dysfunction 
Orgasmic dysfunction (OD) is the inability 
to achieve an orgasm or the markedly 
diminished intensity of an orgasm.[2,14] It can 
also be the marked delay of orgasm during 
any kind of sexual stimulation. Delayed 
ejaculation, retarded ejaculation, and 
inhibited ejaculation are probably the least 
common, least studied, and least understood 
male sexual dysfunctions.[14]
Clinical evaluation
Treatment should be aetiology specific 
and should address infertility in men of a 
ED
Depression TDS
CVDx CVDx and UMC
Fig. 1. The link between erectile dysfunction (ED), depression, testosterone deficiency syndrome (TDS), 
cardiovascular diagnosis (CVDx) and underlying metabolic conditions (UMC).
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reproductive age. Assessment begins by reviewing the conditions 
under which a man is able to ejaculate (e.g. during sleep, masturbation, 
stimulation by partner). If orgasmic attainment had been possible 
previously, the life events and circumstances temporarily related to 
orgasmic cessation are reviewed.[14] The events in question may be 
pharmaceutical or related to congenital problems, illness, trauma, or 
a variety of life stressors and other psychological factors, influenced 
further by societal and religious attitudes. 
Treatment
Regardless of whether a clear pathophysiological cause is present/
absent, patients may be counselled to consider lifestyle changes 
including enjoying more time together to achieve greater intimacy, 
minimising alcohol consumption, making love when not tired and 
practising techniques that maximise penile stimulation, such as 
pelvic floor training.[14] Patient education regarding existing factors 
that can exacerbate OD is an important first step and may represent 
a segue into counselling. Treatment with pharmaceuticals has had 
limited success.[14] No drugs have been approved by regulatory 
agencies for this purpose.
Male hypoactive sexual desire disorder 
Male hypoactive sexual desire disorder is defined as persistently or 
recurrently deficient (or absent) sexual/erotic thoughts or fantasies 
and desire for sexual activity.[2,3] This may be the result of common 
medical conditions including substance-use disorders, social and 
interpersonal factors, or use of pharmacological agents.[30] 
Clinical evaluation
A comprehensive history should address the patient’s sexual 
behaviour, psychological manifestations of sexual stimuli and body 
changes in response to sexually arousing stimuli.[31] Laboratory 
investigations should determine the patient’s serum testosterone and 
prolactin levels. 
Treatment
Treatment should focus initially on targeting and treating sexual 
difficulties, e.g. pain and ED.[30] Furthermore, the clinician should 
assess the patient-partner relationship and teach sexual com-
munication and erotic skills. Finally, the clinician should attempt to 
maximise enhancers (e.g. varied lovemaking, novelty) and reduce 
inhibitors (both physical, e.g. anaemia and thyroid disease, and 
emotional, e.g. anxiety and depression). Testosterone replacement 
therapy may be considered in some cases.
Conclusion
In male sexual dysfunction there are times when psychiatric care 
should be considered, particularly in patients with severe depression, 
substance-use disorders, or abusive and chaotic relationships. 
Objective evidence does not support the use of natural aphrodisiacs 
as an effective treatment for male or female sexual dysfunctions.[32] 
There is, however, a growing database of evidence-based treatments 
for male sexual dysfunctions.
Future treatments for erectile 
dysfunction
• New PDE5 inhibitors (e.g. Udenafil, Avanafil, Mirodenafil)
• Topical alprostadil cream (Topiglan)
• Melanocortin activators.
Take-home messages
• ED shares risk factors with cardiovascular disease.
• ‘The recognition of ED as a warning sign of silent vascular disease 
has led to the concept that a man with ED and no cardiac symptoms 
is a cardiac (or vascular) patient until proven otherwise.’[33]
• Clinical use of validated questionnaires addressing ED may be 
helpful.
• Lifestyle changes and risk factor modification should precede or 
accompany ED treatment.
• PDE5 inhibitors are contraindicated in patients using nitrates.
• PE is more common than ED.
• Patients must be advised that SSRI treatment for PE is off-label.
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